New Treatments in JIA


Date
Wednesday, January 25, 2017 - Thursday, January 25, 2018 12:00 AM   Online, IN

Objectives
At the conclusion of this activity, participants should be able to: 
  1. Recognize the clinical heterogeneity in JIA and identify the subgroup most at risk for serious complications if not adequately treated;
  2. Understand the unpredictable side effect profile of methotrexate and how we are attempting to better predict this; and
  3. Identify where variability in clinical practice in a rare condition such as localized scleroderma may contribute to the challenges in treatment.

Accreditation
The Indiana UniversitySchool of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.The Indiana University School of Medicine designates this live educational activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™.  Physicians should only claim credit commensurate with the extent of their participation in the activity.

The Indiana University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Indiana University School of Medicine designates this live educational activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™.  Physicians should only claim credit commensurate with the extent of their participation in the activity.